Baillie Gifford & CO Lyell Immunopharma, Inc. Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
A detailed history of Baillie Gifford & CO transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 141,949 shares of LYEL stock, worth $146,207. This represents 0.0% of its overall portfolio holdings.
Number of Shares
141,949
Previous 519,998
72.7%
Holding current value
$146,207
Previous $753,000
74.1%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding LYEL
# of Institutions
122Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$20.8 Million30.81% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$15.5 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$15.5 Million13.96% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$13.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$10.4 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $255M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...